PDF(Pubmed)
Abstract：
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease. Its prevalence is increasing with the epidemic of obesity and metabolic syndrome. MASLD progression into metabolic dysfunction-associated steatohepatitis (MASH) and advanced fibrosis may lead to decompensated cirrhosis and development of liver-related events, hepatocellular carcinoma and death. Monitoring disease progression is critical in decreasing morbidity, mortality, need for transplant and economic burden. Assessing for treatment response once FDA-approved medications are available is still an unmet clinical need.
To explore the most up-to-date literature on testing used for monitoring disease progression and treatment response METHODS: We searched PubMed from inception to 15 August 2023, using the following MeSH terms: \'MASLD\', \'Metabolic dysfunction-associated steatotic liver disease\', \'MASH\', \'metabolic dysfunction-associated steatohepatitis\', \'Non-Alcoholic Fatty Liver Disease\', \'NAFLD\', \'non-alcoholic steatohepatitis\', \'NASH\', \'Biomarkers\', \'clinical trial\'. Articles were also identified through searches of the authors\' files. The final reference list was generated based on originality and relevance to this review\'s broad scope, considering only papers published in English.
We have cited 101 references in this review detailing methods to monitor MASLD disease progression and treatment response.
Various biomarkers can be used in different care settings to monitor disease progression. Further research is needed to validate noninvasive tests more effectively.
To explore the most up-to-date literature on testing used for monitoring disease progression and treatment response METHODS: We searched PubMed from inception to 15 August 2023, using the following MeSH terms: \'MASLD\', \'Metabolic dysfunction-associated steatotic liver disease\', \'MASH\', \'metabolic dysfunction-associated steatohepatitis\', \'Non-Alcoholic Fatty Liver Disease\', \'NAFLD\', \'non-alcoholic steatohepatitis\', \'NASH\', \'Biomarkers\', \'clinical trial\'. Articles were also identified through searches of the authors\' files. The final reference list was generated based on originality and relevance to this review\'s broad scope, considering only papers published in English.
We have cited 101 references in this review detailing methods to monitor MASLD disease progression and treatment response.
Various biomarkers can be used in different care settings to monitor disease progression. Further research is needed to validate noninvasive tests more effectively.
摘要：
背景：代谢功能障碍相关的脂肪变性肝病（MASLD）是慢性肝病的最常见原因。其患病率随着肥胖和代谢综合征的流行而增加。MASLD进展为代谢功能障碍相关脂肪性肝炎（MASH）和晚期纤维化可能导致失代偿性肝硬化和肝脏相关事件的发展，肝细胞癌和死亡。监测疾病进展对降低发病率至关重要，死亡率,需要移植和经济负担。一旦FDA批准的药物可用，评估治疗反应仍然是一个未满足的临床需求。
目的：为了探索有关用于监测疾病进展和治疗反应的测试的最新文献方法：我们搜索了PubMed从成立到2023年8月15日，使用以下MeSH术语：\'MASLD\'，“代谢功能障碍相关脂肪变性肝病”，\'MASH\',“代谢功能障碍相关脂肪性肝炎”，\'非酒精性脂肪性肝病\',\'NAFLD\',\'非酒精性脂肪性肝炎\',\'NASH\',\'生物标志物\'，\'临床试验\'。文章还通过搜索作者\'文件来确定。最终的参考列表是基于原创性和与本评论广泛范围的相关性而生成的，只考虑用英语发表的论文。
结果：我们在这篇综述中引用了101篇参考文献，详细介绍了监测MASLD疾病进展和治疗反应的方法。
结论：各种生物标志物可用于不同的护理环境以监测疾病进展。需要进一步的研究来更有效地验证非侵入性测试。
目的：为了探索有关用于监测疾病进展和治疗反应的测试的最新文献方法：我们搜索了PubMed从成立到2023年8月15日，使用以下MeSH术语：\'MASLD\'，“代谢功能障碍相关脂肪变性肝病”，\'MASH\',“代谢功能障碍相关脂肪性肝炎”，\'非酒精性脂肪性肝病\',\'NAFLD\',\'非酒精性脂肪性肝炎\',\'NASH\',\'生物标志物\'，\'临床试验\'。文章还通过搜索作者\'文件来确定。最终的参考列表是基于原创性和与本评论广泛范围的相关性而生成的，只考虑用英语发表的论文。
结果：我们在这篇综述中引用了101篇参考文献，详细介绍了监测MASLD疾病进展和治疗反应的方法。
结论：各种生物标志物可用于不同的护理环境以监测疾病进展。需要进一步的研究来更有效地验证非侵入性测试。
